India Must ‘Hike Health Spending Or Risk Slowdown’
Executive Summary
A US healthcare advocacy group says India’s rapid economic growth will be jeopardized unless the country starts boosting investment to care for its 1.3bn population. It’s clear what the problems are, but India needs to move from ‘issue stating’ to problem solving, the group’s chairman, Kenneth Thorpe, told the Pink Sheet.
You may also be interested in...
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.
FDA Approves First Generic Of Daraprim
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.
Akorn Extends Lenders Standstill With Aim To Sell Company
US generics company Akorn, which has been struggling since Germany’s Fresenius walked away from a $4.3bn merger three years ago, plans to put itself up for sale under an extended standstill agreement with lenders.